Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersNeurology Physician in Norman, OK
NPI: 1215969605Primary Practice Location
NORMAN REGIONAL
3300 Healthplex Pkwy, Norman, OK
Primary Employer
Oklahoma Medical Research Foundation
omrf.org
HQ Phone
Get M.D. Gabriel's Phone Numberphone_androidMobile
Get M.D. Gabriel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOK State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 163 | 188 |
| 2 | 96413Infusion of chemotherapy into a vein up to 1 hour | 28 | 50 |
| 3 | 96415Infusion of chemotherapy into a vein | 28 | 53 |
| 4 | 96375Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | 25 | 55 |
| 5 | J2930Injection, methylprednisolone sodium succinate, up to 125 mg | 25 | 37 |
Autoantibodies identify primary Sjögren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B.
Authors: Judith James, R Scofield, Alan Baer
Publication Date: 2023-09
Authors: Myassar Zarif, Bianca Weinstock Guttman, Mark Gudesblatt, Samuel Hunter, Mahmoud Abdelrazek, Andrew Smith
Journal: Neuroimage Clin
Publication Date: 2024-04-27
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.
Authors: Ulrike Kaunzner, Anne Cross, Benjamin Greenberg, Jeffrey Gelfand, David Hafler, Simon Thebault, Christopher Lock, Lay Kodama, Carolina Ionete, Robert Fallis, Steven Yuen
Journal: JAMA Neurol
Publication Date: 2024-03-11
Lead Sponsor: Yale University
Collaborators: Genentech, Inc.
Intervention / Treatment: OTHER: Placebo, DRUG: Ocrelizumab
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: OTHER: Data Collection
Lead Sponsor: Johns Hopkins University
Collaborators: Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Intervention / Treatment: OTHER: Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, OTHER: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
